Eleven Biotherapeutics, Inc. (NASDAQ:EBIO)’s share price dropped 8.3% during mid-day trading on Tuesday . The stock traded as low as $1.45 and last traded at $1.43. Approximately 206,421 shares traded hands during trading, a decline of 4% from the average daily volume of 215,876 shares. The stock had previously closed at $1.56.

EBIO has been the topic of several research reports. Zacks Investment Research raised Eleven Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 16th. ValuEngine lowered Eleven Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, June 13th.

The stock has a market cap of $22.17 million, a PE ratio of 13.21 and a beta of 3.37. The stock has a 50-day moving average of $1.28 and a 200-day moving average of $1.62.

Eleven Biotherapeutics (NASDAQ:EBIO) last released its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.30) EPS for the quarter. Eleven Biotherapeutics had a return on equity of 4.26% and a net margin of 11.28%. On average, equities research analysts forecast that Eleven Biotherapeutics, Inc. will post ($1.75) earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in EBIO. Spark Investment Management LLC bought a new stake in Eleven Biotherapeutics in the second quarter valued at about $148,000. Vanguard Group Inc. increased its holdings in Eleven Biotherapeutics by 17.4% in the second quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 30,600 shares during the last quarter. Finally, Virtu KCG Holdings LLC bought a new stake in Eleven Biotherapeutics in the second quarter valued at about $175,000. 5.05% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/12/eleven-biotherapeutics-inc-ebio-stock-price-down-8-3.html.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Receive News & Stock Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.